Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
-
Register
- Non-Member - $39
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
Published: May/June 2024
Journal Article
Overview
This one-hour, on-demand, journal article-based activity explores original qualitative research on patient perspectives regarding buprenorphine discontinuation in the treatment of opioid use disorder (OUD). Little is currently known about the causes of medication discontinuation from the patient perspective. Despite buprenorphine and other medications for OUD being the recommended standard care of treatment for OUD and the benefits of positive health and addiction-related outcomes associated with them, half of patients discontinue medication use in the first year of treatment. Emerging in interviews with patients with OUD treated with buprenorphine were three main themes related to medication discontinuation: health system barriers, adverse effects (or apparent adverse events) associated with the medication, and patient motivations. The purpose of this activity is to better understand patient perspectives around themes of discontinuation and to explore some clinical strategies to enhance patient retention.
The target audience for this intermediate continuing education activity includes: physicians, nurse practitioners, PAs, pharmacists, social workers, counselors, and other clinicians, researchers, students, and policymakers.
This activity addresses the following ACGME Core Competencies: Patient Care, Medical Knowledge, Interpersonal and Communication Skills, Practice-Based Learning and Improvement, Professionalism, and Systems-Based Practice.
Article Abstract
Objectives: Buprenorphine and other medications for opioid use disorder (OUD) are recommended as standard of care in the treatment of OUD and are associated with positive health and addiction-related outcomes. Despite benefits, discontinuation is common, with half of patients discontinuing in the first year of treatment. Addressing OUD is a major clinical priority, yet little is known about the causes of medication discontinuation from the patient perspective.
Methods: From March 2021 to April 2022, we conducted qualitative interviews with patients who had discontinued buprenorphine for the treatment of OUD within the past 12 months. Eligible participants were selected from 2 Veterans Health Administration Health Care Systems in Oregon. Coding and analysis were guided by conventional qualitative content analysis.
Results: Twenty participants completed an interview; 90% were White and 90% were male, and the mean age was 54.2 years. Before discontinuation, participants had received buprenorphine for 8.3 months on average (range, 1–40 months); 80% had received buprenorphine for less than 12 months. Qualitative analysis identified the following themes relating to discontinuation: health system barriers (eg, logistical hurdles, rules and policy violations), medication effects (adverse effects; attributed adverse effects, lack of efficacy in treating chronic pain) and desire for opioid use. Patient description of decisions to discontinue buprenorphine could be multicausal, reflecting provider or system-level barriers in interaction with patient complexity or medication ambivalence.
Conclusion: Study results identify several actionable ways OUD treatment could be modified to enhance patient retention.
Learning Objectives
Upon completion, learners will be able to:
- Identify major themes emerging from interviews with patient about their perspectives on buprenorphine discontinuation for opioid use disorder (OUD) treatment.
- Identify several actionable ways that opioid use disorder (OUD) treatment can be modified to enhance patient retention in treatment.
Registration Rates
Rate Description | Rate |
ASAM Member | $0 |
Non-Member | $39 |
Associate Member | $0 |
Resident Member* | $0 |
Student Member* | $0 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Open Registration: 06/03/2024 - 06/01/2027
Close Access Date: 07/01/2027
Course Instructions
- Click on the Contents tab to begin this activity.
- Click View Journal Article and read the journal article in its entirety.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 3 out of 4 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Accreditation & Credit Designation Statements
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity awards 1 Nursing contact hours.
Pharmacy
This activity will offer 1 pharmacy contact hours (1 CEUs). Pharmacists will be asked to provide identifying information (e-Profile ID and DOB in MMDD format) in order to receive credit and allow reporting to CPE Monitor. (UAN: JA0000141-0000-24-017-H99)